Global expansion Observia has established a presence in Paris with a subsidiary in Shanghai and reports 60 percent of turnover international, indicating strong cross-border adoption opportunities for patient engagement and adherence solutions in multiple markets.

Clinical partnerships Recent collaborations with Clinical Ink for US cardiometabolic adherence solutions and ongoing partnerships with Mapi Trust and Kingston University demonstrate a proven path to market through research sites, academic institutions, and trial networks, suggesting SaaS and services play well in trial and healthcare settings.

Behavioral tech Core offerings combine SPUR diagnostic tooling with d.tells AI driven personalization and OPC cloud platform, highlighting a compelling value proposition for healthcare providers seeking evidence-based adherence and patient engagement solutions.

Regulatory ready Observia’s tools are positioned for clinical research and real-world deployment, with licensing partnerships and international distribution channels through Mapi Trust, enabling scaled access to SPUR and related adherence solutions.

Lean growth With a lean team (11-50 employees) and revenue under one million, there is an opportunity to offer tiered enterprise packages, MSP style implementations, and strategic alliances to accelerate sales while maintaining agile delivery.